Polymorphs are described in the present chemical compounds that modulate the activity of kinase, which includes the activity of PI3 kinase, and Compounds, Pharmaceutical compositions, and Methods for treating diseases and conditions associated with kinase activity, which includes The Activity of PI3 Kinase.It is also provided in the present procedures for the preparation of polymorphs of the same compound and Pharmaceutical compositions thereof and the Amorphous form of mismos.reivindicaci\u00f3n 5: Form C Polymorph of a compound of formula (1).Claim 6: The Polymorph according to claim 5, wherein the Polymorph has the following Peaks of x-ray Powder diffraction (XRPD) characteristic: 2Q = 10,4\u00ba (0,2\u00ba), 13,3\u00ba (0,2\u00ba), and 24,3\u00ba (0,2\u00ba). Claim: The 10 polymorphic Form b of a compound of formula (1).Claim: The 11 polymorphic according to claim 10, where the Peaks of XRPD Polymorph has the following characteristic: 2Q = 7,9\u00ba (0,2\u00ba), 13,4\u00ba (0,2\u00ba), and 23,4\u00ba (0,2\u00ba). 15: the claim form (Polymorph of a compound of formula (1).Claim 16: The Polymorph according to claim 15, where the Peaks of XRPD Polymorph has the following characteristic: 2Q = 11,4\u00ba (0,2\u00ba), 17,4\u00ba (0,2\u00ba), and 22,9\u00ba (0,2\u00ba). 20: the claim form and Polymorph of a compound of formula (1).Claim: The 21 polymorphic according to claim 20, where the Peaks of XRPD Polymorph has the following characteristic: 2Q = 6,7\u00ba (0,2\u00ba), 9,3\u00ba (0,2\u00ba), and 24,4\u00ba (0,2\u00ba). 25: the claim form (Polymorph of a compound of formula (1).Claim: The Polymorph 26 according to claim 25, where the Peaks of XRPD Polymorph has the following characteristic: 2Q = 9,6\u00ba (0,2\u00ba), 17,3\u00ba (0,2\u00ba), and 24,6\u00ba (0,2\u00ba). Claim 30 g Shape: The Polymorph of a compound of formula (1).Claim: The 31 polymorphic according to claim 30, where the Peaks of XRPD Polymorph has the following characteristic: 2Q = 6,7\u00ba (0,2\u0
